Patel Chem (544460)

Score breakdown: P/E: 2/3 · ROCE: 2/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• High ROCE of 35.22% shows strong capital efficiency
• Sales growth of 21.98% and profit growth of 17.43% indicate a growing specialty chemicals franchise
• P/E of 14.85 with PEG of 0.75 suggests growth is available at a reasonable price
• Piotroski F-Score of 7/9 points to sound financial health
• Latest quarter annualized profit of roughly ₹24 Cr supports the ₹170 Cr market cap

Concerns

• Profit growth trails sales growth, hinting at possible margin pressure
• No dividend means zero income cushion for shareholders
• Missing data on debt-to-equity, book value, and promoter holding limits a thorough Graham-style check
• Small-cap size with limited disclosure raises execution and governance risks

AI Analysis

Let me start with what I like. Patel Chem earns an impressive 35.22% return on capital employed, which tells me the business can generate strong returns without excessive leverage. The latest quarter shows ₹61 Cr sales and ₹6 Cr net profit, annualized roughly ₹24 Cr against a ₹170 Cr market cap, so the stock is priced at about 14.85 times earnings. For a company growing sales at 21.98% and profits at 17.43%, that is not an expensive price. The PEG ratio of 0.75 suggests growth is available at a discount. Piotroski score of 7 out of 9 also points to healthy fundamentals. But I must be honest about what I cannot see. The company does not give me book value, return on equity, debt-to-equity, or promoter holding. Graham would remind me that the absence of information is not the same as bad news, but an investor should not pay for what he cannot examine. There is no dividend, so shareholders rely entirely on capital appreciation. Also, profit growth is slower than sales growth, which implies margins are under some pressure. That is worth monitoring. At ₹68.50 with a market cap of only ₹170 Cr, this is a small-cap specialty chemical player. Small caps can offer wonderful opportunities, but they demand more caution, not less. The high ROCE and solid growth give me comfort, but I would want to see the balance sheet and cash conversion before making a large commitment. Valuation looks fair, and if the company can maintain its growth and returns, this may be a fine compounder. I would keep position sizing modest and watch the underlying financials closely.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer